The Chinese Hypertrophic Cardiomyopathy Study(CHCS)
关键词
抽象
描述
In the present study, patients with HCM are recruited prospectively after informed consent was given. The investigator will collect the baseline clinical characteristics of the patients at enrollment, including comprehensive physical examination, laboratory testing of blood and urine, electrocardiography, 24-hr Holter, echocardiography, MRI and other examinations if necessary. The specimens retained include blood for all patients and myocardium for patients receive surgery of myocardial myectomy. Multi-omics screening, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, will be performed to identified novel disease genes, signal pathway or processes, genetic risk factors and potential therapy targets of HCM. Furthermore, besides examining the accuracy of SCD risk prediction of the 2011 ACCF/AHA and 2014 ESC guidelines, we will identify novel risk factors associated with the clinical outcomes and construct predictive models suitable for Chinese patients with HCM.
日期
| 最后验证: | 02/28/2018 |
| 首次提交: | 01/25/2016 |
| 提交的预估入学人数: | 02/24/2016 |
| 首次发布: | 03/01/2016 |
| 上次提交的更新: | 03/23/2018 |
| 最近更新发布: | 03/26/2018 |
| 实际学习开始日期: | 03/22/2011 |
| 预计主要完成日期: | 12/30/2025 |
| 预计完成日期: | 12/30/2028 |
状况或疾病
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Hypertrophic cardiomyopathy Individuals with an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM, in the absence of other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy. |
资格标准
| 有资格学习的性别 | All |
| 取样方式 | Non-Probability Sample |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion criteria: Patients with HCM diagnosed by observation of unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM. Exclusion criteria: Individuals with other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy. |
结果
主要结果指标
1. Cardiovascular deaths [an average of 2 years]
次要成果指标
1. all-cause mortality [an average of 2 years.]
2. Heart failure [an average of 2 years]
3. Stroke [an average of 2 years]
4. Malignant arrhythmia [an average of 2 years]
